HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gordon, S. Articles by Plouffe, L. Search for Related Content PubMed PubMed Citation Articles by Gordon, S. Articles by Plouffe, L., Jr Related Collections Menopause and HRT

Transition From Estrogen–Progestin to Raloxifene in Postmenopausal Women: Effect on Vasomotor Symptoms

From the Women’s Health and Internal Medicine, Comprehensive NeuroScience, Inc, Atlanta, Georgia; Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts; Lilly Research Laboratories, Indianapolis, Indiana.

Address reprint requests to: Stephen Gordon, MD, Comprehensive NeuroScience, Inc, Women’s Health and Internal Medicine, 6065 Roswell, Suite 820, Atlanta, GA 30328; e-mail: flashmd_4919{at}msn.com.

OBJECTIVE: To compare vasomotor symptoms after transition from estrogen–progestin therapy to raloxifene 60 mg/d with and without a placebo washout.

METHODS: Postmenopausal women currently taking continuous combined estrogen–progestin therapy (conjugated equine estrogen, 0.625 mg/medroxyprogesterone acetate, 2.5 or 5 mg) daily for 5 or more months were enrolled. Women were randomized to 1 of 4 blinded regimens: 1) 12 weeks estrogen–progestin; 2) 12 weeks placebo; 3) 4 weeks placebo, then 8 weeks raloxifene; or 4) 12 weeks raloxifene. For the final 36 weeks, all subjects received raloxifene. Vasomotor symptoms were assessed by patient diaries.

RESULTS: A total of 266 women (mean age 57.5) were enrolled. Mean hot flush frequency at baseline was approximately 1 per week in the entire population, with 16% of women reporting hot flushes. Mean frequency and severity of hot flushes during the first 12 weeks of the study were statistically greater in the 3 groups transitioned off estrogen–progestin (range of hot flushes per week: 4 weeks, 11–12; 8 weeks, 18–24; 12 weeks, 13–16), as compared with those continuing estrogen–progestin, with no difference between these 3 groups (P.1). Approximately 50–70% of these women reported hot flushes, generally rated as mild to moderate by participants, after estrogen–progestin discontinuation.

CONCLUSION: A large proportion of women discontinuing estrogen–progestin experience hot flushes. Raloxifene does not appear to increase the frequency or severity of vasomotor symptoms in women discontinuing estrogen–progestin more than that observed with placebo treatment after estrogen–progestin discontinuation. Transition from estrogen–progestin to raloxifene with no washout period therefore may be acceptable.

LEVEL OF EVIDENCE: I

This article has been cited by other articles:

				S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial JAMA, June 21, 2006; 295(23): 2742 - 2751. [Abstract] [Full Text] [PDF]

				J. K. Ockene, D. H. Barad, B. B. Cochrane, J. C. Larson, M. Gass, S. Wassertheil-Smoller, J. E. Manson, V. M. Barnabei, D. S. Lane, R. G. Brzyski, et al. Symptom Experience After Discontinuing Use of Estrogen Plus Progestin JAMA, July 13, 2005; 294(2): 183 - 193. [Abstract] [Full Text] [PDF]

				23 Apr 2004 to 23 Jul 2004 Evid. Based Nurs., October 1, 2004; 7(4): e4 - e4. [Full Text] [PDF]

				Vasomotor Symptoms Obstet. Gynecol., October 1, 2004; 104(4_suppl): 106S - 117S. [Full Text] [PDF]

				Other articles noted Evid. Based Med., September 1, 2004; 9(5): e5 - e5. [Full Text] [PDF]